[
  {
    "ts": null,
    "headline": "Sherwin-Williams Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Sherwin-Williams Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b433d2501e7fa9ddb171b5593680042d43a6e2d687fd347e913aabea6764313f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757522460,
      "headline": "Sherwin-Williams Co. stock underperforms Wednesday when compared to competitors",
      "id": 136755261,
      "image": "",
      "related": "SHW",
      "source": "MarketWatch",
      "summary": "Sherwin-Williams Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b433d2501e7fa9ddb171b5593680042d43a6e2d687fd347e913aabea6764313f"
    }
  },
  {
    "ts": null,
    "headline": "Should Softer Sherwin-Williams (SHW) Guidance Prompt a Revisit of Its Earnings Growth Outlook?",
    "summary": "Sherwin-Williams recently reported softer Q2 results, with revenues remaining flat year over year and full-year EPS guidance coming in below analyst expectations. A key insight from these results is that management's outlook has fallen short of consensus estimates despite ongoing efforts to drive growth and margin improvement. We’ll examine how the disappointing full-year EPS guidance may influence Sherwin-Williams’ investment case and risk factors going forward. The end of cancer? These 29...",
    "url": "https://finnhub.io/api/news?id=4325ccf5581e87cd180fe2b4f1d4b2b663d92db17f4411926c4bc41d5eb8b0c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757506160,
      "headline": "Should Softer Sherwin-Williams (SHW) Guidance Prompt a Revisit of Its Earnings Growth Outlook?",
      "id": 136689703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SHW",
      "source": "Yahoo",
      "summary": "Sherwin-Williams recently reported softer Q2 results, with revenues remaining flat year over year and full-year EPS guidance coming in below analyst expectations. A key insight from these results is that management's outlook has fallen short of consensus estimates despite ongoing efforts to drive growth and margin improvement. We’ll examine how the disappointing full-year EPS guidance may influence Sherwin-Williams’ investment case and risk factors going forward. The end of cancer? These 29...",
      "url": "https://finnhub.io/api/news?id=4325ccf5581e87cd180fe2b4f1d4b2b663d92db17f4411926c4bc41d5eb8b0c6"
    }
  }
]